MEDI4736 combined with tremelimumab results in acceptable toxicity in NSCLC patients

Related posts:

1. Portable finger-probe device can successfully measure liver function in potential organ donors A portable, finger-probe device successfully measured liver function in brain dead adult organ donors, a finding that could change the way organs are assessed and save thousands of dollars per transplant, a study has found. ...
2. Chronic myelomonocytic leukemia: JAK2 inhibitor ruxolitinib has promising efficacy Scientists are reporting on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients. ...
3. Phase 2 trial identifies genetic dysfunction that makes many types of cancer vulnerable to an immunotherapy A team of researchers has identified a genetic malfunction that predicts the effectiveness of response to a groundbreaking immunotherapy. The results of their Phase 2 clinical trial reveal that, regardless of its tissue of origin, tumors whose cells are deficient in repairing mismatched DNA sequences--and so preventing mutations--are far more susceptible to the checkpoint inhibitor pembrolizumab than those that retain this ability....
4. ONT-380 has stage IV HER2+ breast cancer patient ‘worrying about normal stuff again’ Promising clinical trial results show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients....
5. Impulsivity linked to binge eating Do you get impulsive when you're upset? If so, this could be putting you at risk for binge eating. The more impulsive you are, the more likely it is you'll binge eat when experiencing negative feelings....